DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)

Information source: Triemli Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Proliferative Diabetic Retinopathy

Intervention: CANAKINUMAB (ILARIS®) (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: PD Dr. med. Stephan Michels

Official(s) and/or principal investigator(s):
Stephan Michels, MD, MBA, Principal Investigator, Affiliation: Department of Ophthalmology, Triemli Hospital Zuerich

Overall contact:
Stephan Michels, MD, MBA, Phone: +41444663200, Email: studien.augenklinik@zuerich.ch

Summary

The pilot study evaluates the efficacy and safety of Canakinumab (ILARIS) in subjects with proliferative diabetic retinopathy secondary to type 1 and 2 diabetes. Ten subjects will be enrolled to receive 150 mg Canakinumab (ILARIS) by subcutaneous injection. Beginning on day 0, each subject will receive a subcutaneous injection of study drug every 8 weeks for 16 weeks, a total of 3 injections. All subjects will undergo regular follow-up assessments every 8 weeks through 24 weeks. Fluorescein angiography (FA) is repeated every 8 weeks. In case of progression of retinal neovascularization on FA panretinal laser photocoagulation is administered as rescue therapy. The primary outcome is the regression of retinal neovascularizations (NVE and NVD) in FA at 24 weeks. In addition to key secondary outcomes including regression of diabetic macular edema, change in best-corrected visual acuity, change in HbA1c levels and change in markers of systemic inflammation. Safety will be assessed by measurements of vital signs, clinical laboratory assessments, and the recording of adverse clinical events.

Clinical Details

Official title: A Pilot Study on the Effects of ILARIS on Patients With Proliferative Diabetic Retinopathy (PDRP)

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Regression of retinal neovascularizations (NVE and NVD) in FA.

Secondary outcome:

Central retinal thickness measured by SD-OCT

Best corrected visual acuity

Change in HbA1c and inflammatory markers

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: Signed and dated Informed Consent American Diabetes Association (ADA) diagnostic criteria for type 1 (TD1) or type 2 (T2D) diabetes Evidence of proliferative diabetic retinopathy with: 1. Active retinal neovascularization defined by fluorescein angiography as non-high risk proliferative diabetic retinopathy (PDRP; NVD < 1/3 disc area; NVE < ½ disc area) or 2. High risk PDRP treated with prior panretinal laser photocoagulation (PRP), showing persistent, active retinal neovascularization. The last session of PRP should not be within 12 weeks prior to enrolment. Diabetes (Type I or II) must be stable which is defined as not requiring a change in medication over the last 4 weeks Age ≥ 18 For female subjects of child-bearing age, a negative serum pregnancy test is mandatory. For subjects with reproductive potential, a willingness to utilize adequate contraception and not become pregnant. Adequate contraceptive measures include oral contraceptives (stable use for two or more cycles prior to Screening); IUD; Depo-Provera®; Norplant® System implants; condom or diaphragm used in conjunction with contraceptive sponge, foam or jelly; and abstinence. Ability to regular follow-up visits

-

Exclusion Criteria: Patients requiring laser coagulation or intravitreal therapy with steroids or anti-VEGF drugs for diabetic macular edema within the first 6 months after enrolment Patients with laser coagulation or any intravitreal therapy within three months prior to enrollment Media opacification not allowing adequate retinal examination Allergy to fluorescein (Fluorescein Angiography) Known HIV antibody, hepatitis B surface antigen, and/or hepatitis C antibody History of malignancy except basal cell skin carcinoma prior to study entry History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibody History or evidence of active tuberculosis (TB) infection at Visit 1 or one of the risk factors for tuberculosis such as residence in a congregate setting (e. g. homeless shelter), substance abuse, health-care workers with unprotected exposure to patients who are at high risk of TB or patients with TB disease, close contact (i. e. share the same air space in a household or other enclosed environment for a prolonged period (days or weeks) with a person with active pulmonary TB disease within the last 12 months History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection, at Visit 1, determined as defined by local guidelines/ local medical practice. If presence of tuberculosis is established then treatment (according to local guidelines) must have been completed prior to randomization Live vaccinations within 3 months prior to the randomization visit or live vaccinations planned during the trial. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes Any biologic drugs targeting the immune system (for example, TNF blockers, anakinra, rituximab, abatacept, tocilizumab) active atopic disease history or symptoms of a demyelinating disease

Locations and Contacts

Stephan Michels, MD, MBA, Phone: +41444663200, Email: studien.augenklinik@zuerich.ch

Department of Ophthalmology, Triemli Hospital Zurich, Zurich 8063, Switzerland; Recruiting
Sarah Eisenstein, Phone: +4144466, Ext: 3200, Email: studien.augenklinik@zuerich.ch
Additional Information

Starting date: April 2012
Last updated: April 27, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017